Linagliptin

Generic Name: Linagliptin

Brand Names: Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₈N_₈O_₂

CAS Number: 668270-12-0

Unique Ingredient Identifier: 3X29ZEJ4R2

Background: Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.

Indication: Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with...

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Pill for type 2 diabetes may control diabetic eye disease

Boehringer Ingelheim and Eli Lilly's Jardiance may prevent worsening of diabetic eye disease in type 2 diabetes patients, per JAMA Ophthalmology. Analysis of over 80,000 patients showed Jardiance users had 22% lower risk of existing diabetic eye disease worsening compared to DPP4 inhibitor users. The study suggests Jardiance's potential benefit in managing diabetic retinopathy.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy